Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis

Amyotrophic Lateral Sclerosis

Volumn 12, Issue 6, 2011, Pages 430-438

  Van Blitterswijk, Marka ^a,e   Gulati, Sunita ^a   Smoot, Elizabeth ^b   Jaffa, Matthew ^b   Maher, Nancy ^c   Hyman, Bradley T ^c   Ivinson, Adrian J ^c   Scherzer, Clemens R ^c,d   Schoenfeld, David A ^b   Cudkowicz, Merit E ^b   Brown Jr , Robert H ^a   Bosco, Daryl A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c The Harvard Center for Neurodegeneration & Repair   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

alzheimer's disease; immunotherapy; parkinson's disease; Sporadic amyotrophic lateral sclerosis; superoxide dismutase

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS; SURVIVAL TIME;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SUPEROXIDE DISMUTASE; SURVIVAL;

EID: 80055044020     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2011.585163     Document Type: Article

References (39)

1. Bosco DA, Landers JE. Genetic determinants minants of amyotrophic lateral sclerosis as therapeutic targets. CNS Neurol Disord Drug Targets. 2010;9:779-90.
2. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851-4. (Pubitemid 28450505)
3. Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal. 2009;11:1603-14.
4. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006;9:108-18. (Pubitemid 43011916)
5. Magrane J, Hervias I, Henning MS, Damiano M, Kawamata H, Manfredi G. Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Hum Mol Genet. 2009;18:4552-64.
6. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One. 2010;5:11552.
7. Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2007;104:2495-500. (Pubitemid 46391424)
8. Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102: 170-8. (Pubitemid 46906269)
9. Bosco DA, Morfi ni G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13:1396-403.
10. Morfi ni GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, et al. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776-86.
11. Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113: 1188-99.
12. Takeuchi S, Fujiwara N, Ido A, Oono M, Takeuchi Y, Tateno M, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase-1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol. 2010;69:1044-56.
13. Ray SS, Nowak RJ, Strokovich K, Brown RH Jr, Walz T, Lansbury PT Jr. An intersubunit disulfi de bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry. 2004; 43:4899-905. (Pubitemid 38544443)
14. Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, Cabelli DE, et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem. 2002;277: 15923-31. (Pubitemid 34967873)
15. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specifi c antibodies by enzymelabeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972;109:129-35.
16. Steinitz M. Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells. Anal Biochem. 2000;282:232-8. (Pubitemid 30439496)
17. McQuillen DP, Gulati S, Ram S, Turner AK, Jani DB, Heeren TC, et al. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J Infect Dis. 1999;179: 124-35. (Pubitemid 29028347)
18. Ngampasutadol J, Rice PA, Walsh MT, Gulati S. Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine. 2006;24: 157-70. (Pubitemid 41753003)
19. Gnehm HE, Pelton SI, Gulati S, Rice PA. Characterization of antigens from non-typeable Haemophilus infl uenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin Invest. 1985;75: 1645-58. (Pubitemid 15039490)
20. Rice PA, Vayo HE, Tam MR, Blake MS. Immunoglobulin G antibodies directed against protein III block killing of serumresistant Neisseria gonorrhoeae by immune serum. J Exp Med. 1986;164:1735-48. (Pubitemid 17184201)
21. Mehta C, Patel N. StatXact8. In: Software CS, editor. Cambridge: MA; 2008.
22. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26:261-92. (Pubitemid 351600377)
23. Knipe DM, Howley PM. In: Knipe DM, Howley PM, editors. Fields Virology. 5th edn. Philidelphia: Lippincott, Williams and Wilkins; 2007.
24. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1 Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18:271-80. (Pubitemid 15023099)
25. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277: 47551-6. (Pubitemid 36159274)
26. Durazo A, Shaw BF, Chattopadhyay M, Faull KF, Nersissian AM, Valentine JS, et al. Metal-free superoxide dismutase-1 and three different ALS variants share a similar partially unfolded {beta}-barrel at physiological temperature. J Biol Chem. 2009;284:34382-9.
27. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-defi cient superoxide dismutase. Science. 1999;286:2498-500.
28. Lindberg MJ, Normark J, Holmgren A, Oliveberg M. Folding of human superoxide dismutase: disulfi de reduction prevents dimerization and produces marginally stable monomers. Proc Natl Acad Sci USA. 2004;101:15893-8. (Pubitemid 39507898)
29. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu/Zn superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem. 2004;279:15499-504. (Pubitemid 38618950)
30. Cimini V, Ruggiero G, Buonomo T, Seru R, Sciorio S, Zanzi C, et al. Cu/Zn superoxide dismutase in human thymus: immunocytochemical localization and secretion in thymusderived epithelial and fi broblast cell lines. Histochem Cell Biol. 2002;118:163-9. (Pubitemid 34983973)
31. Mondola P, Ruggiero G, Seru R, Damiano S, Grimaldi S, Garbi C, et al. The Cu/Zn superoxide dismutase in neuroblastoma SK-N-BE cells is exported by a microvesicles dependent pathway. Brain Res Mol Brain Res. 2003;110: 45-51. (Pubitemid 36165041)
32. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One. 2007;2:1205.
33. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (SALS). J Neuroimmunol. 2005;159:215-24. (Pubitemid 40126195)
34. Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol. 1984;6:51-7. (Pubitemid 14132684)
35. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol. 1990;47:1210-6. (Pubitemid 20381002)
36. Demestre M, Pullen A, Orrell RW, Orth M. ALS-IgGinduced selective motor neuron apoptosis in rat mixed primary spinal cord cultures. J Neurochem. 2005;94:268-75. (Pubitemid 40911412)
37. Smith RG, Alexianu ME, Crawford G, Nyormoi O, Stefani E, Appel SH. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA. 1994;91: 3393-7. (Pubitemid 24130243)
38. Pullen AH, Humphreys P. Ultrastructural analysis of spinal motoneurons from mice treated with IgG from ALS patients, healthy individuals, or disease controls. J Neurol Sci. 2000; 180:35-45.
39. Fridovich I. Superoxide anion radical (O2?.), superoxide dismutases, and related matters. J Biol Chem. 1997;272:18515-7. (Pubitemid 27318184)